Inj, invega sustenna, 1 mg
Products billed under this code include Invega Sustenna.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Invega Sustenna.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Invega Sustenna | Janssen Pharmaceuticals, Inc. | 50458-0560-01 | 39 | $602.043 |
| Invega Sustenna | Janssen Pharmaceuticals, Inc. | 50458-0561-01 | 78 | $1,204.086 |
| Invega Sustenna | Janssen Pharmaceuticals, Inc. | 50458-0562-01 | 117 | $1,806.129 |
| Invega Sustenna | Janssen Pharmaceuticals, Inc. | 50458-0563-01 | 156 | $2,408.172 |
| Invega Sustenna | Janssen Pharmaceuticals, Inc. | 50458-0564-01 | 234 | $3,612.258 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $15.437 | +$0.006 | 1 MG | Inj, invega sustenna, 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $15.431 | +$0.354 | 1 MG | Inj, invega sustenna, 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $15.077 | −$0.034 | 1 MG | Inj, invega sustenna, 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $15.111 | $0.00 | 1 MG | Inj, invega sustenna, 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $15.111 | +$0.027 | 1 MG | Inj, invega sustenna, 1 mg | v1, posted September 8, 2026 |
| 3Q25 | $15.084 | +$0.345 | 1 MG | Inj, invega sustenna, 1 mg | v1, posted March 10, 2026 |
| 2Q25 | $14.739 | +$0.006 | 1 MG | Inj, invega sustenna, 1 mg | v1, posted March 10, 2026 |
| 1Q25 | $14.733 | −$0.029 | 1 MG | Inj, invega sustenna, 1 mg | v1, posted December 19, 2025 |
| 4Q24 | $14.762 | +$0.10 | 1 MG | Inj, invega sustenna, 1 mg | v1, posted June 11, 2025 |
| 3Q24 | $14.662 | +$0.383 | 1 MG | Inj, invega sustenna, 1 mg | v1, posted June 11, 2025 |
| 2Q24 | $14.279 | −$0.039 | 1 MG | Inj, invega sustenna, 1 mg | v1, posted March 11, 2025 |
| 1Q24 | $14.318 | −$0.022 | 1 MG | Inj, invega sustenna, 1 mg | v1, posted December 19, 2024 |
| 4Q23 | $14.34 | +$0.123 | 1 MG | Inj, invega sustenna, 1 mgj | v1, posted October 10, 2024 |
| 3Q23 | $14.217 | +$0.567 | 1 MG | Inj, invega sustenna, 1 mgj | v1, posted June 5, 2024 |
| 2Q23 | $13.65 | +$0.319 | 1 MG | Paliperidone palmitate inj | v1, posted February 23, 2024 |
| 1Q23 | $13.331 | +$0.056 | 1 MG | Paliperidone palmitate inj | v1, posted December 6, 2023 |
| 4Q22 | $13.275 | +$0.143 | 1 MG | Paliperidone palmitate inj | v1, posted June 22, 2023 |
| 3Q22 | $13.132 | +$0.496 | 1 MG | Paliperidone palmitate inj | v1, posted June 9, 2023 |
| 2Q22 | $12.636 | −$0.013 | 1 MG | Paliperidone palmitate inj | v1, posted December 14, 2022 |
| 1Q22 | $12.649 | −$0.014 | 1 MG | Paliperidone palmitate inj | v1, posted June 8, 2022 |
| 4Q21 | $12.663 | +$0.11 | 1 MG | Paliperidone palmitate inj | v1, posted June 2, 2022 |
| 3Q21 | $12.553 | +$0.45 | 1 MG | Paliperidone palmitate inj | v1, posted June 2, 2022 |
| 2Q21 | $12.103 | −$0.019 | 1 MG | Paliperidone palmitate inj | v1, posted March 1, 2022 |
| 1Q21 | $12.122 | – | 1 MG | Paliperidone palmitate inj | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.